These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 7562544)
21. Gender differences in kappa-opioid modulation of cocaine-induced behavior and NMDA-evoked dopamine release. Sershen H; Hashim A; Lajtha A Brain Res; 1998 Aug; 801(1-2):67-71. PubMed ID: 9729284 [TBL] [Abstract][Full Text] [Related]
22. Kappa opioid-mediated behavioral sensitization in the preweanling rat: relationship to Fos immunoreactivity. Collins RL; Zavala AR; Ingersoll VY; Duke MA; Crawford CA; McDougall SA Psychopharmacology (Berl); 1998 Jun; 137(3):282-91. PubMed ID: 9683006 [TBL] [Abstract][Full Text] [Related]
23. U-69593, a kappa opioid receptor agonist, decreases cocaine-induced behavioral sensitization in female rats. Puig-Ramos A; Santiago GS; Segarra AC Behav Neurosci; 2008 Feb; 122(1):151-60. PubMed ID: 18298258 [TBL] [Abstract][Full Text] [Related]
24. Increased locomotor response to amphetamine induced by the repeated administration of the selective kappa-opioid receptor agonist U-69593. Fuentealba JA; Gysling K; Andrés ME Synapse; 2007 Sep; 61(9):771-7. PubMed ID: 17568430 [TBL] [Abstract][Full Text] [Related]
25. Effects of U-50488H and U-50488H withdrawal on c-fos expression in the rat paraventricular nucleus. Correlation with c-fos in brainstem catecholaminergic neurons. Laorden ML; Castells MT; Milanés MV Br J Pharmacol; 2003 Apr; 138(8):1544-52. PubMed ID: 12721110 [TBL] [Abstract][Full Text] [Related]
26. Repeated treatment with the kappa opioid receptor agonist U69593 reverses enhanced K+ induced dopamine release in the nucleus accumbens, but not the expression of locomotor sensitization in amphetamine-sensitized rats. Escobar Adel P; Cornejo FA; Andrés ME; Fuentealba JA Neurochem Int; 2012 Mar; 60(4):344-9. PubMed ID: 22306346 [TBL] [Abstract][Full Text] [Related]
27. Evidence for an involvement of muscarinic cholinergic systems in the induction but not expression of behavioral sensitization to cocaine. Heidbreder CA; Shippenberg TS Synapse; 1996 Oct; 24(2):182-92. PubMed ID: 8890460 [TBL] [Abstract][Full Text] [Related]
28. Kappa opioid agonists produce anxiolytic-like behavior on the elevated plus-maze. Privette TH; Terrian DM Psychopharmacology (Berl); 1995 Apr; 118(4):444-50. PubMed ID: 7568631 [TBL] [Abstract][Full Text] [Related]
29. Chronic kappa opioid receptor antagonism produces supersensitivity to U-50,488H at the hypothalamo-pituitary-adrenocortical (HPA) axis level. Alcaraz C; Milanés MV; Vargas ML J Pharmacol Exp Ther; 1993 Sep; 266(3):1385-9. PubMed ID: 8396634 [TBL] [Abstract][Full Text] [Related]
30. Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning. McLaughlin JP; Land BB; Li S; Pintar JE; Chavkin C Neuropsychopharmacology; 2006 Apr; 31(4):787-94. PubMed ID: 16123754 [TBL] [Abstract][Full Text] [Related]
32. Kappa opioid inhibition of morphine and cocaine self-administration in rats. Glick SD; Maisonneuve IM; Raucci J; Archer S Brain Res; 1995 May; 681(1-2):147-52. PubMed ID: 7552272 [TBL] [Abstract][Full Text] [Related]
33. Lack of effect of kappa-opioid receptor agonism on long-term methamphetamine-induced neurotoxicity in rats. Johnson-Davis KL; Hanson GR; Keefe KA Neurotox Res; 2003; 5(4):273-81. PubMed ID: 12835119 [TBL] [Abstract][Full Text] [Related]
34. Mu-opioid receptors are not involved in acute cocaine-induced locomotor activity nor in development of cocaine-induced behavioral sensitization in mice. Lesscher HM; Hordijk M; Bondar NP; Alekseyenko OV; Burbach JP; van Ree JM; Gerrits MA Neuropsychopharmacology; 2005 Feb; 30(2):278-85. PubMed ID: 15257307 [TBL] [Abstract][Full Text] [Related]
35. Antinociceptive actions of dexmedetomidine and the kappa-opioid agonist U-50,488H against noxious thermal, mechanical and inflammatory stimuli. Idänpään-Heikkilä JJ; Kalso EA; Seppälä T J Pharmacol Exp Ther; 1994 Dec; 271(3):1306-13. PubMed ID: 7996439 [TBL] [Abstract][Full Text] [Related]
36. Differential role of delta-opioid receptors in the development and expression of behavioral sensitization to cocaine. Heidbreder C; Shoaib M; Shippenberg TS Eur J Pharmacol; 1996 Mar; 298(3):207-16. PubMed ID: 8846818 [TBL] [Abstract][Full Text] [Related]
37. Nonopioid actions of the kappa-opioid receptor agonists, U 50488H and U 69593 on electrophysiologic properties of hippocampal CA3 neurons in vitro. Alzheimer C; ten Bruggencate G J Pharmacol Exp Ther; 1990 Nov; 255(2):900-5. PubMed ID: 1978733 [TBL] [Abstract][Full Text] [Related]
38. Exposure to the selective kappa-opioid receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats. Chartoff EH; Potter D; Damez-Werno D; Cohen BM; Carlezon WA Neuropsychopharmacology; 2008 Oct; 33(11):2676-87. PubMed ID: 18185499 [TBL] [Abstract][Full Text] [Related]
39. Differential cardiovascular and renal responses produced by microinjection of the {kappa}-opioid U-50488H [(trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-benzene-acetamide) methane sulfonate] into subregions of the paraventricular nucleus. Gottlieb HB; Varner KJ; Kenigs VA; Cabral AM; Kapusta DR J Pharmacol Exp Ther; 2005 Feb; 312(2):678-85. PubMed ID: 15381735 [TBL] [Abstract][Full Text] [Related]
40. The kappa-opioid receptor agonist U-69593 prevents cocaine-induced phosphorylation of DARPP-32 at Thr(34) in the rat brain. D'Addario C; Di Benedetto M; Candeletti S; Romualdi P Brain Res Bull; 2007 Jun; 73(1-3):34-9. PubMed ID: 17499634 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]